Cargando…

Reversal of Low-Grade Cerebral Edema After Lactulose/Rifaximin Therapy in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

OBJECTIVES: Decreased magnetization transfer ratio (MTR) in the brain characterizes cerebral edema (CE) in patients with liver cirrhosis, but the role of treatment on its reversibility has not been studied in patients who have minimal hepatic encephalopathy (MHE). This study was carried to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rai, Rahul, Ahuja, Chirag K, Agrawal, Swastik, Kalra, Naveen, Duseja, Ajay, Khandelwal, Niranjan, Chawla, Yogesh, Dhiman, Radha K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816249/ https://www.ncbi.nlm.nih.gov/pubmed/26378384 http://dx.doi.org/10.1038/ctg.2015.38

Ejemplares similares

Correlation of HVPG Level with CTP Score, MELD Score, Ascites, Size of Varices, and Etiology in Cirrhotic Patients
por: Ramanathan, Subramaniam, et al.
Publicado: (2016)

Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan
por: Chang, Ching, et al.
Publicado: (2021)

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
por: Paik, Yong-Han, et al.
Publicado: (2005)

Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
por: Hudson, Mark, et al.
Publicado: (2019)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
por: Wang, Zhida, et al.
Publicado: (2018)

Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximin
por: Seifert, Leon Louis, et al.
Publicado: (2021)

Comparison of radiofrequency ablation alone & in combination with percutaneous ethanol injection for management of hepatocellular carcinoma
por: Kalra, Naveen, et al.
Publicado: (2017)

Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis
por: Fu, Jian, et al.
Publicado: (2022)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
por: Wang, Ming-Wei, et al.
Publicado: (2023)

Role of radiofrequency ablation in unresectable hepatocellular carcinoma: An Indian experience
por: Kalra, Naveen, et al.
Publicado: (2013)

Profile of Hepatic Encephalopathy in Children with Cirrhosis and Response to Lactulose
por: Sharma, Praveen, et al.
Publicado: (2011)

Lactulose/rifaximin: Lack of drug effect: case report
Publicado: (2021)

Reduction in Gastrointestinal Cancers in Cirrhotic Patients Receiving Rifaximin vs Lactulose Only Therapy for Hepatic Encephalopathy
por: Patel, Ankoor H, et al.
Publicado: (2023)

Minimal Hepatic Encephalopathy in Indians: Psychometric Hepatic Encephalopathy Score and Inhibitory Control Test for Diagnosis and Rifaximin or Lactulose for Its Reversal
por: Pawar, Vinay B., et al.
Publicado: (2019)

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013)

Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial
por: Naderian, Mohammadreza, et al.
Publicado: (2017)

Monocyte human leukocyte antigen – Antigen D related, neutrophil oxidative burst and cytokine analysis in patients of decompensated cirrhosis with and without acute-on chronic liver failure
por: Satsangi, Sandeep, et al.
Publicado: (2018)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

The Use of Rifaximin in Patients With Cirrhosis
por: Caraceni, Paolo, et al.
Publicado: (2021)

Animal Naming Test – a simple and accurate test for diagnosis of minimal hepatic encephalopathy and prediction of overt hepatic encephalopathy
por: Agarwal, Ankit, et al.
Publicado: (2020)

Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)
por: de Wit, K, et al.
Publicado: (2020)

Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Rezaie, Ali, et al.
Publicado: (2019)

Primary prophylaxis of hepatic encephalopathy in decompensated cirrhosis: Low dose vs. full dose rifaximin
por: Sarwar, Shahid, et al.
Publicado: (2019)

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome
por: Yu, Xiao, et al.
Publicado: (2022)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

Determination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects
por: Bae, Suhyun, et al.
Publicado: (2015)

Rifaximin as a rare cause of rhabdomyolysis in cirrhosis
por: Rezigh, Alec B., et al.
Publicado: (2018)

Rifaximin has the potential to prevent complications of cirrhosis
por: Flamm, Steven L., et al.
Publicado: (2018)

Multistrain probiotic and lactulose in the treatment of minimal hepatic encephalopathy
por: Shavakhi, Ahmad, et al.
Publicado: (2014)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
por: Jesudian, Arun B., et al.
Publicado: (2020)

Faecal bacterial microbiota in patients with cirrhosis and the effect of lactulose administration
por: Sarangi, Aditya Narayan, et al.
Publicado: (2017)

Lactulose in cirrhosis: Current understanding of efficacy, mechanism, and practical considerations
por: Bloom, Patricia P., et al.
Publicado: (2023)

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2020)

Use Of Quantitative Modelling To Elucidate The Roles Of The Liver, Gut, Kidney, And Muscle In Ammonia Homeostasis And How Lactulose And Rifaximin Alter This Homeostasis
por: Levitt, Michael D, et al.
Publicado: (2019)

Comparative Analysis of the Efficacy of Different Regimens of 12 Months Rifaximin-Alfa Therapy in Patients with Liver Cirrhosis and Minimal Hepatic Encephalopathy
por: Bakulin, Igor G., et al.
Publicado: (2023)

Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
por: Nishida, Shinya, et al.
Publicado: (2019)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_adfrls2b9cjp55vl3ui1sbc40u